Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV community study of recombinant Mycobacterium tuberculosis fusion protein (EC) skin test
ChiCTR2300070447Phase 4Not yet recruiting
- Sponsor
- Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
- Start
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of C-Tb in Tuberculosis (TB) (2 cohorts), sponsored by Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention. Primary endpoints: Red halo transverse and longitudinal diameters and Induration transverse and longitudinal diameters. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
C-Tb
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR2300070447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070447.